Pharma Mar (OTCMKTS:PHMMF) Short Interest Update

Pharma Mar (OTCMKTS:PHMMF) was the recipient of a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 252 shares, a decline of 99.3% from the June 15th total of 34,651 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

Pharma Mar Trading Down 3.6%

PHMMF stock traded down $3.44 during trading on Friday, hitting $90.90. The company had a trading volume of 102 shares, compared to its average volume of 27. The business has a 50 day moving average of $95.96 and a 200 day moving average of $93.82. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.44 and a current ratio of 3.02. Pharma Mar has a fifty-two week low of $77.41 and a fifty-two week high of $110.40.

Analyst Ratings Changes

Several equities research analysts have commented on PHMMF shares. Chardan Capital upgraded shares of Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. Zacks Research upgraded Pharma Mar to a “hold” rating in a research report on Monday, June 15th. Finally, BTIG Research assumed coverage on Pharma Mar in a report on Thursday, April 23rd. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy”.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.